Cargando…

Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI

Bile salt export pump (BSEP) inhibition has been proposed to be an important mechanism for drug-induced liver injury (DILI). Modeling can prioritize knowledge gaps concerning bile acid (BA) homeostasis and thus help guide experimentation. A submodel of BA homeostasis in rats and humans was construct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woodhead, J L, Yang, K, Brouwer, K L R, Siler, S Q, Stahl, S H, Ambroso, J L, Baker, D, Watkins, P B, Howell, B A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120015/ https://www.ncbi.nlm.nih.gov/pubmed/25006780 http://dx.doi.org/10.1038/psp.2014.21

Ejemplares similares

MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics
por: Yang, Y., et al.
Publicado: (2014)

Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition
por: Beaudoin, James J., et al.
Publicado: (2023)

Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury
por: Woodhead, Jeffrey L., et al.
Publicado: (2014)

A Mechanistic Model of Drug-Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial
por: Howell, B A, et al.
Publicado: (2014)

Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury
por: Longo, Diane M, et al.
Publicado: (2019)

Mechanistic Studies of Idiosyncratic DILI: Clinical Implications
por: Uetrecht, Jack
Publicado: (2019)

Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI
por: Stern, Sydney, et al.
Publicado: (2023)

Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity
por: Yang, Kyunghee, et al.
Publicado: (2014)

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors
por: Woodhead, Jeffrey L., et al.
Publicado: (2017)

Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling
por: Woodhead, Jeffrey L, et al.
Publicado: (2022)

The DILI‐sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation
por: Watkins, Paul B.
Publicado: (2019)

Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure
por: Liu, Anika, et al.
Publicado: (2021)

Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses
por: Shoda, Lisl KM, et al.
Publicado: (2017)

Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters
por: Yang, K, et al.
Publicado: (2017)

Causality Assessment for Suspected DILI During Clinical Phases of Drug Development
por: Regev, Arie, et al.
Publicado: (2014)

The Promise of AI for DILI Prediction
por: Vall, Andreu, et al.
Publicado: (2021)

Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling
por: Woodhead, Jeffrey L., et al.
Publicado: (2019)

Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug‐Induced Liver Injury
por: Longo, DM, et al.
Publicado: (2016)

Biomarkers in DILI: One More Step Forward
por: Robles-Díaz, Mercedes, et al.
Publicado: (2016)

Mechanistic Investigations Support Liver Safety of Ubrogepant
por: Smith, Brenda, et al.
Publicado: (2020)

Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development
por: Roth, Sharin E., et al.
Publicado: (2019)

Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
por: Stephens, Camilla, et al.
Publicado: (2012)

Factors limiting immunization coverage in urban Dili, Timor-Leste
por: Amin, Ruhul, et al.
Publicado: (2013)

Clinical management of patients with drug‐induced liver injury (DILI)
por: Björnsson, Einar S.
Publicado: (2021)

Landscape of DILI-related adverse drug reaction in China Mainland
por: Wang, Jiabo, et al.
Publicado: (2022)

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
por: Hey-Hadavi, Juliana, et al.
Publicado: (2021)

Modeling Drug- and Chemical-Induced Hepatotoxicity with Systems Biology Approaches
por: Bhattacharya, Sudin, et al.
Publicado: (2012)

Using Quantitative Systems Toxicology to Investigate Observed Species Differences in CKA-Mediated Hepatotoxicity
por: Battista, Christina, et al.
Publicado: (2018)

Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes
por: Quintás, Guillermo, et al.
Publicado: (2021)

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
por: Moreno-Torres, Marta, et al.
Publicado: (2022)

Quantitative systems toxicology (QST) reproduces species differences in PF‐04895162 liver safety due to combined mitochondrial and bile acid toxicity
por: Generaux, Grant, et al.
Publicado: (2019)

Seroprevalence and prevention of hepatitis B, measles and rubella among healthcare workers in Dili, Timor-Leste
por: Gusmao, Celia, et al.
Publicado: (2023)

The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative
por: Bessone, Fernando, et al.
Publicado: (2016)

Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives
por: Kuna, Lucija, et al.
Publicado: (2018)

Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues
por: Teschke, Rolf, et al.
Publicado: (2021)

Comment: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment
por: Danjuma, Mohammed, et al.
Publicado: (2020)

Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)—In Vitro Testing
por: Tátrai, Péter, et al.
Publicado: (2022)

Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials
por: Longo, DM, et al.
Publicado: (2017)

Prediction of Safety Margin and Optimization of Dosing Protocol for a Novel Antibiotic using Quantitative Systems Pharmacology Modeling
por: Woodhead, Jeffrey L., et al.
Publicado: (2018)

Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling
por: Woodhead, J. L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vqip76jrc62l47mvhm1crn0ii5